POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium is the primary intracellular cation, essential for nerve impulse transmission, muscle contraction, and acid-base balance. Replacement therapy with potassium chloride corrects hypokalemia by increasing extracellular potassium concentration, restoring normal membrane potential and cellular function.
| Metabolism | Not metabolized; excreted primarily by the kidneys via tubular secretion and passive diffusion. |
| Excretion | Renal: >90% of potassium chloride is excreted unchanged in urine via glomerular filtration and tubular secretion. Fecal/biliary elimination is negligible (<2%) under normal renal function. |
| Half-life | Terminal half-life: 2-4 hours in patients with normal renal function. In renal impairment, half-life may be prolonged up to 12-24 hours, increasing risk of hyperkalemia. |
| Protein binding | Potassium is not protein-bound; exists as free ion. Serum protein binding: <2% (negligible). |
| Volume of Distribution | Apparent Vd: 0.2-0.3 L/kg (total body water). Potassium is primarily intracellular (98%), with only 2% in extracellular fluid. Vd increases in hypokalemia and decreases in hyperkalemia. |
| Bioavailability | Oral: 90-100% (well absorbed from gastrointestinal tract). Intravenous: 100% (complete bioavailability by design). |
| Onset of Action | Intravenous: Immediate (seconds to minutes) based on infusion rate; clinical effect (serum potassium elevation) occurs within 30-60 minutes of starting infusion. Oral: 1-2 hours after ingestion. |
| Duration of Action | Intravenous: 4-6 hours depending on dose and renal function; continuous infusion maintains steady state. Oral: 6-8 hours for sustained-release formulations. |
| Molecular Weight | 74.55 |
Intravenous infusion; rate not to exceed 10 mEq/hour (10 mmol/hour) or 0.02 mEq/kg/min (0.02 mmol/kg/min) for adults; maximum concentration 40 mEq/L (40 mmol/L) via peripheral vein; typical dose 20-40 mEq (20-40 mmol) per day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR > 50 mL/min: no adjustment. GFR 10-50 mL/min: reduce dose by 25-50% and monitor serum potassium. GFR < 10 mL/min: avoid or use with extreme caution; maximum dose 20 mEq/day with close monitoring. |
| Liver impairment | No specific adjustment required; however, monitor serum potassium in patients with severe hepatic impairment due to risk of hyperkalemia. |
| Pediatric use | Intravenous infusion; dose 0.5-1 mEq/kg (0.5-1 mmol/kg) per dose, maximum 1 mEq/kg/hour (1 mmol/kg/hour); maximum concentration 40 mEq/L (40 mmol/L) via peripheral vein. |
| Geriatric use | Use with caution; consider reduced baseline renal function; initial dose at lower end of adult range; monitor serum potassium and renal function closely; maximum infusion rate 5 mEq/hour (5 mmol/hour) in elderly. |
| 1st trimester | Potassium chloride and sodium chloride are essential electrolytes. Use is generally safe when clinically indicated, as hypokalemia or hyponatremia pose greater risks. However, excessive doses may lead to hyperkalemia or hypernatremia, which can adversely affect maternal and fetal health. Monitoring is recommended. |
| 2nd trimester | Same as first trimester. Normal maintenance doses are considered safe, but caution is required to avoid electrolyte imbalances that could precipitate preterm labor or other complications. |
| 3rd trimester | Use with caution to avoid fluid overload or electrolyte disturbances, which may affect uterine perfusion or fetal well-being. Close monitoring of maternal electrolytes and fluid status is essential. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | There is some placental transfer of potassium and chloride ions, but they are actively regulated by the placenta. Maternal electrolyte levels are closely reflected in fetal circulation. Excessive maternal doses or imbalances can affect fetal electrolyte status. |
| Breastfeeding | Both potassium and sodium are normal constituents of breast milk. Supplementation at usual doses does not pose a risk to the infant. However, maternal electrolyte balance should be maintained to avoid excessive transfer. Monitor infant for signs of electrolyte imbalance if high doses are used. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Potassium chloride at physiologic concentrations is not teratogenic. No evidence of fetal harm at standard replacement doses. However, hyperkalemia or hypokalemia may adversely affect fetal development. First trimester: No known teratogenic risk. Second trimester: No known teratogenic risk. Third trimester: No known teratogenic risk; but maternal electrolyte imbalance can affect fetal cardiac function. |
| Fetal Monitoring | Monitor serum potassium levels, renal function, and ECG during infusion. In pregnancy, additional monitoring of maternal fluid balance, urine output, and fetal heart rate if maternal hyperkalemia or hypokalemia develops. |
| Fertility Effects | No known direct effect on fertility. However, severe electrolyte disturbances may impair reproductive function. |
■ FDA Black Box Warning
Concentrated potassium solutions must be diluted before administration; rapid infusion can cause fatal hyperkalemia and cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHypernatremiaSevere renal impairmentAnuriaAcidosis with hyperkalemiaAdrenal insufficiency (Addison's disease)
| Precautions | Monitor serum potassium levels and ECG during administration; use with caution in patients with renal impairment, cardiac disease, or conditions predisposing to hyperkalemia; avoid rapid infusion; ensure adequate urinary output. |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, tomatoes, spinach, avocados) and potassium-containing salt substitutes to prevent hyperkalemia. Limit sodium intake if hypertensive or fluid-overloaded. |
| Clinical Pearls | This solution provides 20 mEq/L of potassium and 154 mEq/L of sodium. Use with caution in patients with renal impairment, hyperkalemia, or conditions predisposing to hyperkalemia. Monitor serum potassium and ECG during infusion. Not for direct IV push; administer via IV infusion only. Incompatible with amiodarone, amphotericin B, and phenytoin. |
| Patient Advice | Report any pain, redness, or swelling at the IV site. · Tell your healthcare provider if you have muscle weakness, irregular heartbeat, or tingling sensations. · This medication contains potassium; avoid potassium-rich foods and salt substitutes unless directed by your doctor. · Do not change the infusion rate yourself. |
Loading safety data…